Scleroderma

HomePatientsLung Disease Week at the ATS2019Scleroderma ▶ Information for Experts
Information for Experts

sclero

Annals of ATS

Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II
2018
Link to Abstract

Does Systemic Sclerosis–associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression
2019
Link to Abstract

 

AJRCCM

Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
2018
Link to Abstract

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis
2019
Link to Abstract

Disconnect between Fibrotic Response and Right Ventricular Dysfunction
2019
Link to Abstract

Type I Collagen-Targeted PET Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies
2019
Link to Abstract

Detection of Pediatric Pulmonary Arterial Hypertension by School Electrocardiography Mass Screening
2019
Link to Abstract

 

AJRCMB

Sirtuin1 Protects against Systemic Sclerosis–related Pulmonary Fibrosis by Decreasing Proinflammatory and Profibrotic Processes
2018
Link to Abstract

 

ATS Statements, Guidelines, Reports:

An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis

An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research

 

Disclaimer:
"The ATS Lung Disease Week Web site is designed for educational purposes only. You should not rely on this information as a substitute for personal medical attention, a diagnosis from a physician, or direct medical care. If you are concerned about your health or that of a family member, please consult your family's healthcare provider immediately. Do not wait for a response from our members, staff or partners.”